Active	Status	Sponsor type	Region	Phase	Filter
4 Active 7 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Brandwein, Joseph
NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML	Recruiting	3	322	Europe, Canada, US	Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF	Arog Pharmaceuticals, Inc.	Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations	10/24	10/24
TWT-202, NCT04730258: A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML	Recruiting	1/2	72	Canada, US, RoW	CFI-400945, CFI-400945 fumarate, 945, 400945, Azacitidine	Treadwell Therapeutics, Inc	Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML, MDS, CMML	01/26	01/26
DSP-5336-101, NCT04988555: A Study of DSP-5336 in Relapsed/refractory AML/ ALL with or Without MLL Rearrangement or NPM1 Mutation	Recruiting	1/2	70	Europe, Canada, Japan, US, RoW	DSP-5336	Sumitomo Pharma America, Inc.	Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute	01/25	02/25
Shaikh, Ovais
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) Jan 2024 - Dec 2024: Approval for myelofibrosis Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis Feb 2024 - Feb 2024: Completion of P2b trial for JIA Feb 2024 - Feb 2024: Exclusivity expiry in US	Active, not recruiting	3	430	Europe, Canada, US, RoW	Pelabresib, Ruxolitinib, Placebo	Constellation Pharmaceuticals	Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis	08/23	12/27